首頁 > 市場調查報告書 > 製藥

自體免疫疾病

市場調查報告書

商品編碼

1616797

自體免疫疾病診斷市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Autoimmune Disease Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年09月18日 | 出版商:

Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023年，全球自體免疫疾病診斷市場估值為53億美元，預計2024年至2032年複合年成長率為5.9%。的日益採用推動的。當免疫系統因潛在的異常而錯誤地攻擊人體細胞時，就會出現自體免疫疾病。當免疫系統無法辨識其細胞時，就會發生這種故障，導致產生針對健康組織的自身抗體。為了解決這個問題，各個組織正在實施舉措，以提高對自體免疫疾病及其社會經濟影響的認知。

這些努力導致全球對診斷測試的需求更高。此外，實驗室自動化和技術的進步有助於自體免疫疾病診斷領域的發展。市場按產品類型分類，特別是試劑、消耗品和儀器。試劑和耗材領域佔據最大的市場佔有率，到 2023 年將產生約 35 億美元的收入。

隨著需要這些測試的患者人數的增加，對試劑和耗材的需求也相應增加。診斷技術的不斷進步，包括酶聯免疫吸附測定 (ELISA)、聚合酶鏈反應 (PCR) 和免疫螢光測定，增加了對專用試劑的需求。依疾病類型分類，市場分為全身性自體免疫疾病及局部自體免疫疾病。局部自體免疫疾病領域在2023 年以約37 億美元的收入引領市場，預計複合年成長率為5.7%。需要定期進行檢查監測和頻繁評估。在北美，自體免疫疾病診斷市場到 2023 年將產生 19 億美元的收入，預計在預測期內將出現顯著成長。預計到2030 年，光是美國市場就將超過29 億美元。行業參與者的存在。隨著意識和技術的發展，自體免疫疾病診斷市場有望強勁成長。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	53億美元
預測值	90 億美元
複合年成長率	5.9%

。

產業生態系統分析
產業影響力
- 成長動力
  - 自體免疫疾病的高發生率和盛行率
  - 人們對自體免疫疾病的認知不斷提高
  - 政府對自體免疫疾病研究活動的支持政策
  - 技術進步和實驗室自動化技術的日益採用
- 產業陷阱與挑戰
  - 設立診斷中心需要大量資金投入
  - 測試結果週轉時間慢並且需要進行多次診斷測試
成長潛力分析
技術景觀
未來市場趨勢
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

主要趨勢
試劑及耗材
儀器儀表

第 6 章：市場估計與預測：按疾病類型，2021 - 2032

主要趨勢
系統性自體免疫疾病
- 類風濕關節炎
- 系統性紅斑狼瘡（SLE）
- 牛皮癬
- 多發性硬化症
- 其他系統性自體免疫疾病
局限性自體免疫疾病
- 發炎性腸道疾病
- 1 型糖尿病
- 甲狀腺
- 其他局部自體免疫疾病

第 7 章：市場估計與預測：按測試類型，2021 - 2032

主要趨勢
抗核抗體測試
自體抗體測試
C反應蛋白（CRP）
全血球計數 (CBC)
尿液分析
其他測試

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院
診斷中心
其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Abbott Laboratories
Bio-rad Laboratories, Inc.
DIAsource ImmunoAssays SA
Euroimmun AG (Perkin Elmer)
F. Hoffmann-la Roche Ltd.
Hemagen Diagnostics
Myriad Genetics
Quest Diagnostics
Siemens Healthineers Inc.
SQI Diagnostics Inc.
Thermo Fisher Scientific Inc.
Trinity Biotech Plc.

簡介目錄

Product Code: 618

The Global Autoimmune Disease Diagnostics Market was valued at USD 5.3 billion in 2023 and is projected to grow at a CAGR of 5.9% from 2024 to 2032. This growth is primarily driven by the increasing prevalence of autoimmune disorders and the growing adoption of automated diagnostic equipment. Autoimmune diseases arise when the immune system erroneously attacks the body's cells due to underlying abnormalities. This malfunction can occur when the immune system fails to recognize its cells, leading to the production of autoantibodies that target healthy tissues. To combat this issue, various organizations are implementing initiatives to enhance awareness of autoimmune diseases and their socioeconomic implications.

These efforts are resulting in a higher demand for diagnostic tests worldwide. Furthermore, advancements in laboratory automation and technology contribute to the growth of the autoimmune disease diagnostics sector. The market is categorized by product types, specifically reagents and consumables and instruments. The reagents and consumables segment held the largest market share, generating approximately USD 3.5 billion in revenue in 2023. This segment's growth is fueled by the rising number of autoimmune diseases, leading to an increased need for diagnostic testing.

As the patient population requiring these tests grows, the demand for reagents and consumables rises correspondingly. Continuous advancements in diagnostic technologies, including enzyme-linked immunosorbent assays (ELISA), polymerase chain reaction (PCR), and immunofluorescence assays, have created a heightened need for specialized reagents. When examined by disease type, the market is divided into systemic autoimmune diseases and localized autoimmune diseases. The localized autoimmune disease segment led the market with revenues of around USD 3.7 billion in 2023, and it is expected to experience a CAGR of 5.7%.The high prevalence of localized autoimmune disorders drives the demand for diagnostic testing, as these conditions often necessitate regular monitoring and frequent assessments. In North America, the autoimmune disease diagnostics market generated USD 1.9 billion in revenue in 2023, and significant growth is anticipated over the forecast period. The U.S. market alone is expected to exceed USD 2.9 billion by 2030. This substantial market share can be attributed to several factors, including the rising burden of autoimmune diseases, increased healthcare spending, new product launches, and the presence of key industry players in the region. As awareness and technology evolve, the market for autoimmune disease diagnostics is poised for robust growth.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$5.3 Billion
Forecast Value	$9 Billion
CAGR	5.9%

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 High incidence and prevalence of autoimmune diseases
  - 3.2.1.2 Growing awareness about autoimmune diseases
  - 3.2.1.3 Supportive government policies for research activities on autoimmune diseases
  - 3.2.1.4 Technological advancements and increasing adoption of lab automation technologies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Need for high capital investment in setting-up diagnosis centers
  - 3.2.2.2 Slow turnaround time for test results and need for multiple diagnostic tests
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Reagents and consumables
5.3 Instruments

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Systemic autoimmune disease
- 6.2.1 Rheumatoid arthritis
- 6.2.2 Systemic lupus erythematosus (SLE)
- 6.2.3 Psoriasis
- 6.2.4 Multiple sclerosis
- 6.2.5 Other systemic autoimmune diseases
6.3 Localized autoimmune disease
- 6.3.1 Inflammatory bowel disease
- 6.3.2 Type 1 diabetes
- 6.3.3 Thyroid
- 6.3.4 Other localized autoimmune diseases

Chapter 7 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Antinuclear antibody tests
7.3 Autoantibody tests
7.4 C-reactive protein (CRP)
7.5 Complete blood count (CBC)
7.6 Urinalysis
7.7 Other tests

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Diagnostics centers
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa